Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Kantoff, M.D.

Co-Author

This page shows the publications co-authored by Philip Kantoff and Anthony D'Amico.
Connection Strength

10.385
  1. Reply to G. Francolini et al. J Clin Oncol. 2021 11 20; 39(33):3764-3765.
    View in: PubMed
    Score: 0.959
  2. Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. J Clin Oncol. 2021 09 10; 39(26):2938-2947.
    View in: PubMed
    Score: 0.945
  3. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply. JAMA. 2016 Mar 08; 315(10):1055-6.
    View in: PubMed
    Score: 0.654
  4. Long-term Follow-up of a Randomized Trial of Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2015 Sep 22-29; 314(12):1291-3.
    View in: PubMed
    Score: 0.631
  5. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):10-5.
    View in: PubMed
    Score: 0.406
  6. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer. 2008 Dec 15; 113(12):3290-7.
    View in: PubMed
    Score: 0.396
  7. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008 Jun 20; 26(18):2979-83.
    View in: PubMed
    Score: 0.383
  8. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23; 299(3):289-95.
    View in: PubMed
    Score: 0.372
  9. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007 Jun 10; 25(17):2420-5.
    View in: PubMed
    Score: 0.357
  10. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18; 292(7):821-7.
    View in: PubMed
    Score: 0.294
  11. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer. 2002 Jul 15; 95(2):275-80.
    View in: PubMed
    Score: 0.254
  12. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. Cancer. 2021 08 01; 127(15):2623-2630.
    View in: PubMed
    Score: 0.232
  13. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000 Sep 13; 284(10):1280-3.
    View in: PubMed
    Score: 0.224
  14. Time to Prostate-specific Antigen Nadir and the Risk of Death From Prostate Cancer Following Radiation and Androgen Deprivation Therapy. Urology. 2019 04; 126:145-151.
    View in: PubMed
    Score: 0.199
  15. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. J Natl Compr Canc Netw. 2018 06; 16(6):727-734.
    View in: PubMed
    Score: 0.191
  16. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. Cancer. 2018 04 01; 124(7):1391-1399.
    View in: PubMed
    Score: 0.186
  17. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer. 2018 04 01; 124(7):1383-1390.
    View in: PubMed
    Score: 0.185
  18. Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 May 01; 3(5):652-658.
    View in: PubMed
    Score: 0.177
  19. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Prostate Cancer Prostatic Dis. 2017 06; 20(2):234-240.
    View in: PubMed
    Score: 0.174
  20. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death. Prostate Cancer Prostatic Dis. 2017 03; 20(1):79-84.
    View in: PubMed
    Score: 0.171
  21. Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial. J Clin Oncol. 2016 11 01; 34(31):3781-3786.
    View in: PubMed
    Score: 0.171
  22. Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer. Prostate Cancer. 2014; 2014:230812.
    View in: PubMed
    Score: 0.144
  23. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer. 2014 Jun 15; 120(12):1787-93.
    View in: PubMed
    Score: 0.142
  24. Natural history of untreated prostate specific antigen radiorecurrent prostate cancer in men with favorable prognostic indicators. Prostate Cancer. 2014; 2014:912943.
    View in: PubMed
    Score: 0.142
  25. Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial. Cancer. 2013 Sep 15; 119(18):3280-6.
    View in: PubMed
    Score: 0.136
  26. Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):82.
    View in: PubMed
    Score: 0.132
  27. Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. BJU Int. 2012 Nov; 110(9):1252-6.
    View in: PubMed
    Score: 0.125
  28. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol. 2012 Feb; 13(2):189-95.
    View in: PubMed
    Score: 0.121
  29. Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol. 2011 Dec 10; 29(35):4682-7.
    View in: PubMed
    Score: 0.121
  30. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys. 2011 Apr 01; 79(5):1318-22.
    View in: PubMed
    Score: 0.110
  31. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer. 2010 Feb 01; 116(3):610-5.
    View in: PubMed
    Score: 0.107
  32. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol. 2009 Dec 10; 27(35):6000-5.
    View in: PubMed
    Score: 0.105
  33. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1046-52.
    View in: PubMed
    Score: 0.105
  34. Postrandomization analysis assessing survival following radiation therapy (RT) with or without 6 months of androgen suppression therapy (AST) for localized prostate cancer (PCa). J Clin Oncol. 2009 May 20; 27(15_suppl):5129.
    View in: PubMed
    Score: 0.102
  35. Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):337-41.
    View in: PubMed
    Score: 0.101
  36. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May; 71(5):933-7.
    View in: PubMed
    Score: 0.094
  37. Aspirin and hormone therapy for prostate cancer. N Engl J Med. 2007 Dec 27; 357(26):2737-8.
    View in: PubMed
    Score: 0.093
  38. Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference. J Urol. 2007 Sep; 178(3 Pt 2):S5-8; quiz S4.
    View in: PubMed
    Score: 0.090
  39. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5.
    View in: PubMed
    Score: 0.074
  40. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5.
    View in: PubMed
    Score: 0.070
  41. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003 Nov 01; 21(21):3979-86.
    View in: PubMed
    Score: 0.069
  42. Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol. 2000 Sep 15; 18(18):3240-6.
    View in: PubMed
    Score: 0.056
  43. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. J Clin Oncol. 2020 09 10; 38(26):3032-3041.
    View in: PubMed
    Score: 0.055
  44. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol. 2000 Jun; 163(6):1797-801.
    View in: PubMed
    Score: 0.055
  45. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019 09 25; 10(1):4358.
    View in: PubMed
    Score: 0.052
  46. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy. Urology. 1998 Feb; 51(2):287-92.
    View in: PubMed
    Score: 0.047
  47. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36.
    View in: PubMed
    Score: 0.037
  48. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718.
    View in: PubMed
    Score: 0.036
  49. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1471-9.
    View in: PubMed
    Score: 0.035
  50. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Sep; 10(9):1081-7.
    View in: PubMed
    Score: 0.032
  51. Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. J Urol. 2012 Jun; 187(6):2068-73.
    View in: PubMed
    Score: 0.031
  52. Low rate of clinician-scored gynecomastia induced by 6 months of combined androgen blockade in a randomized trial: Implications for prophylactic breast irradiation. Pract Radiat Oncol. 2012 Jul-Sep; 2(3):172-178.
    View in: PubMed
    Score: 0.030
  53. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15; 82(4):1411-6.
    View in: PubMed
    Score: 0.029
  54. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200.
    View in: PubMed
    Score: 0.027
  55. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7.
    View in: PubMed
    Score: 0.025
  56. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol. 2008 Jun; 179(6):2181-5; discussion 2185-6.
    View in: PubMed
    Score: 0.024
  57. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Aug; 5(7):650-83.
    View in: PubMed
    Score: 0.023
  58. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56.
    View in: PubMed
    Score: 0.018
  59. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6.
    View in: PubMed
    Score: 0.016
  60. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002 Mar; 1(2):203-9.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.